What is the 13F Pro Quality Score for CON?

13F Pro ranks Concentra Group Holdings Parent, Inc. (CON) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View CON's current score at https://13fpro.ai/company/CON (free sign-up required for the full ranking).

Which hedge funds own the most CON stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of CON include BlackRock,, PRICE T ROWE ASSOCIATES /MD/, VANGUARD PORTFOLIO MANAGEMENT. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/company/CON as soon as new 13F filings post.

Where does 13F Pro source CON data?

All Concentra Group Holdings Parent, Inc. fundamentals and ownership data come directly from SEC EDGAR. Concentra Group Holdings Parent, Inc. files with the SEC under CIK 2014596. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is CON in?

Concentra Group Holdings Parent, Inc. (CON) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

What drives CON's revenue?

Per Concentra Group Holdings Parent, Inc.'s latest 10-Q filed with the SEC on 2026-08-06, the biggest revenue drivers are: Occupational health centers ($553.5M); Workers' compensation ($361.2M); Employer services ($183.2M). Figures are extracted from the filing text and machine-verified against the document. Full breakdown at https://13fpro.ai/company/CON.

What are CON's largest expenses?

Concentra Group Holdings Parent, Inc.'s latest 10-Q reports these as the largest expense items: Cost of services ($413.9M, 68.3% of revenue vs 70.7% prior year); General and administrative ($56.7M, 9.4% of revenue vs 9.6% prior year); Depreciation and amortization ($19.9M). Sourced directly from SEC EDGAR filing text for Q2 FY2026 (quarter ended June 30, 2026).

How often is CON research updated on 13F Pro?

CON's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Concentra Group Holdings Parent, Inc.(CON)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →NYSEmid

Institutional-grade research for retail investors

SEC EDGAR: CIK 2014596 CON stock profile & AI dashboard →

13F Pro Quality Score

64.3/100

Rank #559 of 2,962 stocksTOP 25%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

59.7/100

Profitability

63.3/100

Balance Sheet

76.6/100

Earnings Quality

78.9/100

Free Cash Flow

59.2/100

Institutional Flow

61.5/100

Revenue Scale

65.3/100

Dilution Risk

75.8/100

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why CON Scores 64/100

exact factor attribution · 2026-09-11

CON's composite is driven by earnings quality and capital efficiency. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Earnings quality

+2.9 pts

79th pct

Capital efficiency

+2.7 pts

77th pct

Scale

+2.3 pts

65th pct

Profitability

+2.0 pts

63th pct

Revenue growth

+1.9 pts

60th pct

Free cash flow

+1.4 pts

59th pct

Shareholder dilution

+1.3 pts

76th pct

Institutional flow

+0.6 pts

62th pct

Earnings growth

-0.8 pts

34th pct

Latest change (2026-08-06): 69 → 64 · ↓ Revenue growth 80→52; ↓ Earnings growth 64→44

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

CON Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for Concentra Group Holdings Parent, Inc. (CON), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores CON at 64.3/100 on a 32-signal composite quality model, placing it at rank #559 of 2,962 stocks — the top 25% of the AI-ranked universe. CON scores in the top quartile across earnings quality (78.9), balance sheet strength (76.6). Based on the latest XBRL financial filings (Q2 2026), Concentra Group Holdings Parent, Inc. reports quarterly revenue of $606.0M, net income of $65.3M, an operating margin of 19.0%. Top institutional holders of CON by reported 13-F value include BlackRock, PRICE T ROWE ASSOCIATES, VANGUARD PORTFOLIO MANAGEMENT, based on the most recent SEC filings. CON trades on the NYSE exchange and files with the SEC under CIK 2014596. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CON daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Concentra Group Holdings Parent, Inc. directly from SEC EDGAR. Concentra Group Holdings Parent, Inc.'s 13F Pro composite quality score has ranged between 55 and 68 since 2025, currently 64.3 — an improving long-term trajectory across 52 quarterly and live scoring snapshots.

What's Driving CON's Business? Latest 10-Q Breakdown

✓ 30/30 datapoints verified

AI-extracted from Concentra Group Holdings Parent, Inc.'s 10-Q filed 2026-08-06 — Q2 FY2026 (quarter ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.

Revenue grew 10.0% YoY to $606.0M in Q2 FY2026, with operating margin expanding to 19.0% from 16.3% as cost of services fell to 68.3% of revenue.

Biggest Revenue Drivers

Occupational health centers$553.5M

91% of revenue; driven by organic increases in patient visit volume and revenue per visit

Onsite health clinics$38.8Mvs $22.6M prior year

Growth driven by the June 2025 acquisition of Pivot Onsite Innovations, adding over 240 onsite locations

Biggest Revenue Drivers

Total revenue: $606.0M+10.0% YoY

Occupational health centers$553.5M

91% of revenue; driven by organic increases in patient visit volume and revenue per visit

Within Occupational health centers

Workers' compensation$361.2M

Higher reimbursement rates under state fee schedules; revenue per visit up 4.9% to $219.06

Employer services$183.2M

Revenue per visit up 3.2% to $95.84 on rate increases

Onsite health clinics$38.8Mvs $22.6M prior year

Growth driven by the June 2025 acquisition of Pivot Onsite Innovations, adding over 240 onsite locations

Other businesses$13.7M

Includes Concentra Telemed, Concentra Pharmacy, and Concentra Medical Compliance Administration

Largest Expense Items

Cost of services$413.9M68.3% of revenue vs 70.7% prior year

Decreased as % of revenue due to increased staffing efficiencies and elimination of one-time Nova expenses via synergies

General and administrative$56.7M9.4% of revenue vs 9.6% prior year

One-time Nova and Pivot expenses in 2025 offset by new hires, stock compensation, and standalone public company costs

Depreciation and amortization$19.9M

Increase primarily due to recent growth through de novos and acquisitions

Interest expense$25.7Mdown from $28.2M

Decrease due to term loan amortization and repayment of $85M Revolving Credit Facility borrowings

Margins: Income from operations margin expanded to 19.0% from 16.3% YoY, driven by cost of services falling to 68.3% of revenue from 70.7% on staffing efficiencies and the elimination of one-time Nova acquisition costs incurred in the prior-year quarter.

Watch Items from the Filing

A qui tam lawsuit unsealed November 10, 2025 alleges the Company's physical therapy referral guidelines led to false claims submitted to insurers, following a related California Department of Insurance subpoena from February 2024.
A DOJ False Claims Act investigation into physical therapy billing (originally targeting former parent Select) continues, with a related qui tam suit unsealed in May 2024; Concentra is not a named defendant but is cooperating.
The PJ&A third-party vendor data breach affected almost four million patients; six consolidated class actions remain pending, though the Company does not expect a material financial impact.
Leverage ratio was 2.99x versus a covenant maximum of 6.5x, and $430.2M remained available under the Revolving Credit Facility, indicating substantial balance sheet flexibility.
Occupational health centers remained 91% of revenue (down from 94% a year ago) as onsite health clinics grew to 7% following the Pivot acquisition, showing gradual diversification.

AI-extracted and verified against SEC EDGAR filing text. Not investment advice.

Read the full 10-Q on SEC EDGAR →Share on X

Revenue

Q2 2026

$606.0M

Net Income

Q2 2026

$65.3M

Free Cash Flow

Q2 2026

$119.5M

Operating Margin

Q2 2026

19.0%

ROIC

Q2 2026

22.4%

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+13.9% YoY

$2.16BFY 2025

FY22 $1.72BFY23 $1.84BFY24 $1.90BFY25 $2.16B

Net Income

-0.1% YoY

$166.4MFY 2025

FY22 $166.7MFY23 $179.9MFY24 $166.5MFY25 $166.4M

Operating Income

+9.6% YoY

$334.0MFY 2025

FY22 $258.5MFY23 $287.6MFY24 $304.8MFY25 $334.0M

EPS (Diluted)

-11.0% YoY

$1.30FY 2025

FY22 $1.60FY23 $1.73FY24 $1.46FY25 $1.30

Total Assets

+13.4% YoY

$2.86BFY 2025

FY22 $2.30BFY23 $2.33BFY24 $2.52BFY25 $2.86B

Total Debt

+6.4% YoY

$1.57BFY 2025

FY22 —FY23 $4.7MFY24 $1.48BFY25 $1.57B

Op. Cash Flow

+1.7% YoY

$279.4MFY 2025

FY22 $274.3MFY23 $234.3MFY24 $274.7MFY25 $279.4M

Free Cash Flow

-6.3% YoY

$197.1MFY 2025

FY22 $228.4MFY23 $169.4MFY24 $210.3MFY25 $197.1M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Revenue	$2.16B +13.9%	$1.90B +3.4%	$1.84B +6.6%	$1.72B	—
Net Income	$166.4M -0.1%	$166.5M -7.4%	$179.9M +7.9%	$166.7M	—
Operating Income	$334.0M +9.6%	$304.8M +6.0%	$287.6M +11.3%	$258.5M	—
EPS (Diluted)	$1.30 -11.0%	$1.46 -15.6%	$1.73 +8.1%	$1.60	—
Total Assets	$2.86B +13.4%	$2.52B +8.0%	$2.33B +1.6%	$2.30B	—
Total Debt	$1.57B +6.4%	$1.48B +31063.3%	$4.7M	—	—
Operating Cash Flow	$279.4M +1.7%	$274.7M +17.2%	$234.3M -14.6%	$274.3M	—
Free Cash Flow	$197.1M -6.3%	$210.3M +24.2%	$169.4M -25.8%	$228.4M	—

Get alerted when CON's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Concentra Group Holdings Parent, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of CON

BlackRock, Inc.
$528.2M17,753,714 sh
PRICE T ROWE ASSOCIATES INC /MD/
$527.0M17,715,257 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$202.8M6,817,456 sh
VANGUARD CAPITAL MANAGEMENT LLC
$152.6M5,129,815 sh
STATE STREET CORP
$144.0M4,840,099 sh
JENNISON ASSOCIATES LLC
$96.9M3,256,435 sh
DIMENSIONAL FUND ADVISORS LP
$96.0M3,225,694 sh
GEODE CAPITAL MANAGEMENT, LLC
$92.2M3,099,790 sh
Invesco Ltd.
$87.0M2,922,867 sh
JPMORGAN CHASE & CO
$82.9M2,780,432 sh

Fund	Value	Shares
BlackRock, Inc.	$528.2M	17,753,714
PRICE T ROWE ASSOCIATES INC /MD/	$527.0M	17,715,257
VANGUARD PORTFOLIO MANAGEMENT LLC	$202.8M	6,817,456
VANGUARD CAPITAL MANAGEMENT LLC	$152.6M	5,129,815
STATE STREET CORP	$144.0M	4,840,099
JENNISON ASSOCIATES LLC	$96.9M	3,256,435
DIMENSIONAL FUND ADVISORS LP	$96.0M	3,225,694
GEODE CAPITAL MANAGEMENT, LLC	$92.2M	3,099,790
Invesco Ltd.	$87.0M	2,922,867
JPMORGAN CHASE & CO	$82.9M	2,780,432

Companies Similar to CON

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

ADUS

Addus HomeCare Corp

AI score

Similar quality profile · 12 shared holders

Tributary Capital Management, LLC Dana Investment Advisors, Inc.Moran Wealth Management, LLC

GRDN

Guardian Pharmacy Services, Inc.

AI score

Similar quality profile · 9 shared holders

T. Rowe Price Investment Management, Inc.JENNISON ASSOCIATES LLC LOOMIS SAYLES & CO L P

EHC

Encompass Health Corp

AI score

Similar quality profile · 8 shared holders

JENNISON ASSOCIATES LLC LOOMIS SAYLES & CO L P T. Rowe Price Investment Management, Inc.

Pediatrix Medical Group, Inc.

AI score

Similar quality profile · 12 shared holders

ROYCE & ASSOCIATES LP Dana Investment Advisors, Inc.Phocas Financial Corp.

DGX

QUEST DIAGNOSTICS INC

AI score

Similar quality profile · 5 shared holders

Ceredex Value Advisors LLC FIRST NATIONAL BANK OF OMAHA CSM Advisors, LLC

WST

WEST PHARMACEUTICAL SERVICES INC

AI score

Similar quality profile · 4 shared holders

T. Rowe Price Investment Management, Inc.CRAMER ROSENTHAL MCGLYNN LLC Susquehanna Portfolio Strategies, LLC

UHS

UNIVERSAL HEALTH SERVICES INC

AI score

Similar quality profile · 8 shared holders

First Eagle Investment Management, LLC HOTCHKIS & WILEY CAPITAL MANAGEMENT LLC ROYCE & ASSOCIATES LP

ITGR

Integer Holdings Corp

AI score

Similar quality profile · 13 shared holders

HBK INVESTMENTS L P Tributary Capital Management, LLC Dana Investment Advisors, Inc.

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put CON on your watchlist

Track score changes the day Concentra Group Holdings Parent, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is CON a good stock to buy?

13F Pro's AI-powered analysis of Concentra Group Holdings Parent, Inc. (CON) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for CON are available on the CON stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. CON is classified as a mid company.

Which hedge funds own CON?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling CON. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Concentra Group Holdings Parent, Inc.'s investment landscape.